Vaccination with a Modified vaccinia virus Ankara-based vaccine protects mice from allergic sensitization

Journal of Gene Medicine

Volumn 10, Issue 12, 2008, Pages 1324-1333

  Albrecht, Melanie ^a   Suezer, Yasemin ^a   Staib, Caroline ^b   Sutter, Gerd ^a   Vieths, Stefan ^a   Reese, Gerald ^a  

^a PAUL EHRLICH INSTITUT   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

IgE; Modified vaccinia virus Ankara; Specific immunotherapy

Indexed keywords

ALUMINUM POTASSIUM SULFATE; IMJECT OVA; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; OVALBUMIN; UNCLASSIFIED DRUG; VIRUS VECTOR; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHEMOSENSITIZATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOOD ALLERGY; GENE EXPRESSION; GENETIC TRANSDUCTION; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPROPHYLAXIS; IMMUNOTHERAPY; MAST CELL LEUKEMIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TH1 CELL; VACCINATION; VACCINE PRODUCTION; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM; ANIMAL; BAGG ALBINO MOUSE; GENETICS; HYPERSENSITIVITY; IMMUNOLOGY;

ANIMALIA; MAMMALIA; MURINAE; MUS; RATTUS; VACCINIA VIRUS ANKARA;

ANIMALS; FEMALE; HYPERSENSITIVITY; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; OVALBUMIN; RATS; TH1 CELLS; VACCINES; VACCINIA VIRUS;

EID: 58949102419     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1256     Document Type: Article

References (51)

1. Sampson HA. Update on food allergy. J Allergy Clin Immunol 2004; 113: 805-819.
2. Sicherer SH, Munoz-Furlong A, Sampson HA. Prevalence of seafood allergy in the United States determined by a random telephone survey. J Allergy Clin Immunol 2004; 114: 159-165.
3. Rona RJ, Keil T, Summers C, et al. The prevalence of food allergy: a meta-analysis. J Allergy Clin Immunol 2007; 120: 638-646.
4. Mills EN, Mackie AR, Burney P, et al. The prevalence, cost and basis of food allergy across Europe. Allergy 2007; 62: 717-722.
5. Nelson HS, Lahr J, Rule R, Bock A, Leung D. Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J Allergy Clin Immunol 1997; 99: 744-751.
6. Oppenheimer JJ, Nelson HS, Bock SA, Christensen F, Leung DY. Treatment of peanut allergy with rush immunotherapy. J Allergy Clin Immunol 1992; 90: 256-262.
7. Enrique E, Cistero-Bahima A. Specific immunotherapy for food allergy: basic principles and clinical aspects. Curr Opin Allergy Clin Immunol 2006; 6: 466-469.
8. Halken S. Prevention of allergic disease in childhood: clinical and epidemiological aspects of primary and secondary allergy prevention. Pediatr Allergy Immunol 2004; 15(Suppl 16): 4-32.
9. Hamelmann E, Beyer K, Gruber C, et al. Primary prevention of allergy: avoiding risk or providing protection? Clin Exp Allergy 2008; 38: 233-245.
10. Saxon A. What impact will the immune tolerance network have on the future treatment of allergic diseases? Clin Exp Allergy 2004; 34: 1657-1659.
11. Greer FR, Sicherer SH, Burks AW. Effects of early nutritional interventions on the development of atopic disease in infants and children: the role of maternal dietary restriction, breastfeeding, timing of introduction of complementary foods, and hydrolyzed formulas. Pediatrics 2008; 121: 183-191.
12. Akdis M, Verhagen J, Taylor A, et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 2004; 199: 1567-1575.
13. Schnierle BS, Suezer Y, Sutter G. Recombinant poxvirus vaccines in biomedical research. In Poxviruses, Mercer AA, Schmidt A, Weber O (eds). Publisher: Birkhäuser, Basel, 2007; 311-327.
14. Antoine G, Scheiflinger F, Dorner F, Falkner FG. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 1998; 244: 365-396.
15. Sutter G, Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci USA 1992; 89: 10847-10851.
16. Stickl H, Hochstein-Mintzel V, Mayr A, et al. [MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's translation)]. Dtsch Med Wochenschr 1974; 99: 2386-2392.
17. Vollmar J, Arndtz N, Eckl KM, et al. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine 2006; 24: 2065-2070.
18. Stittelaar KJ, Kuiken T, de Swart RL, et al. Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine 2001; 19: 3700-3709.
19. McConkey SJ, Reece WH, Moorthy VS, et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 2003; 9: 729-735.
20. Amara RR, Villinger F, Altman JD, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001; 292: 69-74.
21. Sutter G, Wyatt LS, Foley PL, Bennink JR, Moss B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 1994; 12: 1032-1040.
22. Harrop R, Connolly N, Redchenko I, et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin Cancer Res 2006; 12: 3416-3424.
23. Garcia-Hernandez E, Gonzalez-Sanchez JL, Andrade-Manzano A, et al. Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther 2006; 13: 592-597.
24. Dorrell L, Yang H, Ondondo B, et al. Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine. J Virol 2006; 80: 4705-4716.
25. McFadden G. Poxvirus tropism. Nat Rev Microbiol 2005; 3: 201-213.
26. Liu L, Chavan R, Feinberg MB. Dendritic Cells are preferentially targeted among hematolymphocytes by modified vaccinia virus Ankara and play a key role in the induction of virus-specific T cell responses in vivo. BMC Immunol 2008; 9: 15.
27. Waibler Z, Anzaghe M, Ludwig H, et al. Modified vaccinia virus Ankara induces Toll-like receptor-independent type I interferon responses. J Virol 2007; 81: 12102-12110.
28. Ramirez JC, Gherardi MM, Esteban M. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J Virol 2000; 74: 923-933.
29. Staib C, Drexler I, Sutter G. Construction and isolation of recombinant MVA. Methods Mol Biol 2004; 269: 77-100.
30. Staib C, Drexler I, Ohlmann M, et al. Transient host range selection for genetic engineering of modified vaccinia virus Ankara. Biotechniques 2000; 28: 1137-1136, 1148.
31. Kaul S, Luttkopf D, Kastner B, et al. Mediator release assays based on human or murine immunoglobulin E in allergen standardization. Clin Exp Allergy 2007; 37: 141-150.
32. Hoffmann A, Vieths S, Haustein D. Biologic allergen assay for in vivo test allergens with an in vitro model of the murine type I reaction. J Allergy Clin Immunol 1997; 99: 227-232.
33. Morafo V, Srivastava K, Huang CK, et al. Genetic susceptibility to food allergy is linked to differential TH2-TH1 responses in C3H/HeJ and BALB/c mice. J Allergy Clin Immunol 2003; 111: 1122-1128.
34. Seitzer U, Bussler H, Kullmann B, et al. Mouse strain specificity of the IgE response to the major allergens of Phleum pratense. Int Arch Allergy Immunol 2005; 136: 347-355.
35. Coffman RL, Seymour BW, Lebman DA, et al. The role of helper T cell products in mouse B cell differentiation and isotype regulation. Immunol Rev 1988; 102: 5-28.
36. Finkelman FD, Holmes J, Katona IM, et al. Lymphokine control of in vivo immunoglobulin isotype selection. Annu Rev Immunol 1990; 8: 303-333.
37. Kleine-Tebbe J, Erdmann S, Knol EF, et al. Diagnostic tests based on human basophils: potentials, pitfalls and perspectives. Int Arch Allergy Immunol 2006; 141: 79-90.
38. Kundig TM, Senti G, Schnetzler G, et al. Der p. 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol 2006; 117: 1470-1476.
39. Gabler M, Scheiblhofer S, Kern K, et al. Immunization with a low-dose replicon DNA vaccine encoding Phl p. 5 effectively prevents allergic sensitization. J Allergy Clin Immunol 2006; 118: 734-741.
40. Scheiblhofer S, Gabler M, Leitner WW, et al. Inhibition of type I allergic responses with nanogram doses of replicon-based DNA vaccines. Allergy 2006; 61: 828-835.
41. Umetsu DT, A kbari O, DeKruyff RH. Regulatory T cells control the development of allergic disease and asthma. J Allergy Clin Immunol 2003; 112: 480-487.
42. Taams LS, Palmer DB, A kbar AN, et al. Regulatory T cells in human disease and their potential for therapeutic manipulation. Immunology 2006; 118: 1-9.
43. Gavin AL, Barnes N, Dijstelbloem HM, Hogarth PM. Identification of the mouse IgG3 receptor: implications for antibody effector function at the interface between innate and adaptive immunity. J Immunol 1998; 160: 20-23.
44. Perlmutter RM, Hansburg D, Briles DE, Nicolotti RA, Davie JM. Subclass restriction of murine anti-carbohydrate antibodies. J Immunol 1978; 121: 566-572.
45. Slack J, Der-Balian GP, Nahm M, Davie JM. Subclass restriction of murine antibodies. II. The IgG plaque-forming cell response to thymus-independent type 1 and type 2 antigens in normal mice and mice expressing an X-linked immunodeficiency. J Exp Med 1980; 151: 853-862.
46. Abdelmoula M, Spertini F, Shibata T, et al. IgG3 is the major source of cryoglobulins in mice. J Immunol 1989; 143: 526-532.
47. Baudino L, Azeredo dS, Nakata M, Izui S. Molecular and cellular basis for pathogenicity of autoantibodies: lessons from murine monoclonal autoantibodies. Springer Semin Immunopathol 2006; 28: 175-184.
48. Snapper CM, McIntyre TM, Mandler R, et al. Induction of IgG3 secretion by interferon gamma: a model for T cell-independent class switching in response to T cell-independent type 2 antigens. J Exp Med 1992; 175: 1367-1371.
49. Rochlitz C, Figlin R, Squiban P, et al. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med 2003; 5: 690-699.
50. Wang Z, La Rosa C, Maas R, et al. Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus. J Virol 2004; 78: 3965-3976.
51. Sudowe S, Montermann E, Steitz J, et al. Efficacy of recombinant adenovirus as vector for allergen gene therapy in a mouse model of type I allergy. Gene Ther 2002; 9: 147-156.